This study was carried out by Prof. Qiang Liu (Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University). In the study, researchers found that the palbociclib-resistant breast cancer ...
Chromosome 13q linkage promotes RB1 hemizygosity during BRCA2 LOH, lowering the ‘two-hit’ barrier and predisposing to ...
SAN ANTONIO — For patients with advanced hormone receptor-positive, HER2-negative breast cancer, health-related quality of life is the same whether they receive CDK4/6 inhibitors in the first or ...
Anticancer agents that inhibit tumor growth by targeting a cell-cycle regulatory protein called CDK4 might actually promote the development and progression of certain B-cell lymphomas. The research ...
This study is carried out by Prof. Qiang Liu (Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University). In this study, researchers found that the palbociclib-resistant breast cancer ...
AstraZeneca secures EU approval for Etcamah in combination with a CDK4/6 inhibitor for first-line treatment of advanced ...
In a phase 3 trial-based cost-effectiveness analysis for advanced breast cancer, treatment with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the second line rather than the first line ...
Cancer cells are even smarter than scientists previously believed, according to new CU Boulder research. When these cells are confronted with potent new drugs called CDK2 inhibitors, which are ...
Morning Overview on MSN
A cancer drug just became the first FDA-cleared treatment for a common breast-cancer subtype
Patients with the most common molecular subtype of advanced breast cancer now have a targeted drug approved specifically for ...
Anticancer agents that inhibit tumor growth by targeting a regulatory protein called CDK4 might actually promote the development and progression of certain B-cell lymphomas, according to a new study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results